Compare Johnson Controls International PLC (JCI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs Neurocrine Biosciences Inc — how do they compare? Johnson Controls International PLC trades at $156.33 (market cap $93.28B), while Neurocrine Biosciences Inc trades at $141.13 (market cap $14.36B). The key difference: Johnson Controls International PLC is far larger — about 6.5× Neurocrine Biosciences Inc's market cap, and Johnson Controls International PLC pays a 1.04% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson Controls International PLC for 65 Days and Neurocrine Biosciences Inc for 23 Days on average.
| JCI | NBIX | |
|---|---|---|
Market Cap | $93.28B | $14.36B |
Volume | 2,786,476 | 1,237,180 |
Sector | Basic Materials | Health |
52-Week High | $158.76 | $185.50 |
52-Week Low | $105.55 | $123.10 |
Typical Hold Time | 65 Days | 23 Days |
Enterprise Value | $102.12B | $14.37B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JCI trades at $155.93, down 1.78% on the day, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported robust Q3 2026 earnings, beating estimates with $1.42 EPS and raising full-year guidance, driven by 10% organic sales growth and a record $21 billion backlog. Profitability remains solid with a 14.32% net income margin and 24.42% ROE.
The stock offers upside to the $172.50 consensus price target, supported by strong fundamentals and institutional accumulation. Risks include elevated valuation multiples (P/E 43.38) and potential macroeconomic pressures on industrial demand. Continued execution on data center and building systems growth is key for sustained momentum.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
